What do studies and labels say about noopept dosage?
| Source | Tablet strength and pack |
|---|---|
| Vidal entry | Ten-milligram tablets, 50 per pack1 |
| Developers' review (Ostrovskaia 2002) | 5 and 10 mg tablets, under clinical assessment in 20022 |
The Russian label starts noopept at twenty milligrams a day as two doses of ten milligrams and raises it to thirty milligrams a day as three such doses if the effect is insufficient and tolerability good; no US label turned up.1
Strengths and the label schedule
The table is set at the top of the page
The Vidal entry, a Russian drug reference's reproduction of the manufacturer's instruction, lists one tablet strength, ten milligrams.1 It gives twenty milligrams a day as two doses of ten milligrams, in the morning and in the daytime, to start.1 The step is to thirty milligrams a day as three doses of ten milligrams, if the effect is insufficient and tolerability good.1 The Vidal entry gives this schedule for memory, attention and other cognitive disorders, including after head injury, in vascular brain insufficiency and in asthenic disorders, and lists age under 18 as a contraindication.1 The label states no maximum dose, and thirty milligrams a day is the highest step it gives.1
No US label or approved dose turned up, and a 2022 FDA warning letter to a seller of "Noopept Powder" says the claims on its website, social media and packaging establish that its products are unapproved new drugs.3
Doses in human trials
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Amelin 2011 | 20 mg daily4 | 60 patients with stroke and mild cognitive impairment, open prospective study, main group compared with controls | 2 months of dosing (the record also says 12 months)4 |
| Mordyk 2009 (tuberculosis study) | 10 mg twice daily5 | 60 patients with newly diagnosed respiratory tuberculosis on antituberculous drugs, 30 of them (group 1) on noopept | First month5 |
The EEG study (Bochkarev 2008) names no dose, size or duration in its summary, and the two Neznamov noopept and piracetam records (2009 and 2008) have no summary to quote.678
Powder, mixing and other routes
The label covers tablets taken by mouth, after food, and nothing else.1 No label, regulator page or maker's leaflet in the pack says how to mix noopept powder, which water to use or how much, or how to draw it into a syringe. Nothing in the label or the trials in the pack covers sublingual or nasal dosing in people.
Storing tablets
The Vidal entry says to store the tablets dry and protected from light, at not above 25 °C, with a shelf life of three years.1 The pack holds no storage data for a mixed noopept solution.
Frequently asked questions
Is there a latest time of day for a noopept dose?
The Vidal entry says not to take it later than six in the evening.1
What do Milligram users log for noopept?
Milligram has no share of people logging noopept to report.
References
- Vidal (Russian drug reference). Ноопепт инструкция по применению: показания, противопоказания, побочное действие – описание Noopept таблетки 10 мг: 50 шт. (45352) - справочник препаратов и лекарств. vidal.ru
- PubMed. [The original novel nootropic and neuroprotective agent noopept]. 2002. pubmed.ncbi.nlm.nih.gov
- FDA. Crystal Clear Supplements - 620285 - 02/04/2022. fda.gov
- PubMed. [Noopept in the treatment of mild cognitive impairment in patients with stroke]. 2011. pubmed.ncbi.nlm.nih.gov
- PubMed. [Prevention of neuro- and cardiotoxic side effects of tuberculosis chemotherapy with noopept]. 2009. pubmed.ncbi.nlm.nih.gov
- PubMed. [Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin]. 2008. pubmed.ncbi.nlm.nih.gov
- PubMed. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. 2009. pubmed.ncbi.nlm.nih.gov
- PubMed. [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin]. 2008. pubmed.ncbi.nlm.nih.gov